Methamphetamine
Mechanism :
A sympathomimetic amine which Inhibits reuptake and metabolism of catecholamines through inhibition of monoamine transporters and oxidase.
Indication :
- Attention-deficit/hyperactivity disorder (ADHD)
- Exogenous obesity
- Off-label: Narcolepsy
Contraindications :
Hypersensitivity to amphetamine or any component of the formulation; during or within 14 days following MAO inhibitors, glaucoma; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncrasy to sympathomimetic amines; agitated state; patients with a history of drug abuse.
Dosing :
ADHD:
Children ≥6 years and Adolescents:
Oral: Initial: 5 mg once or twice daily; may increase in 5 mg increments at weekly intervals until optimum response is achieved; usual maintenance dose: 20 to 25 mg daily in 1 or 2 divided doses.
Exogenous obesity:
Children ≥12 years and Adolescents:
Oral: 5 mg 30 minutes before each meal; treatment duration should not exceed a few weeks.
Adverse Effect :
Hypertension, increased blood pressure, palpitations, tachycardia, Dizziness, drug dependence (prolonged use), dysphoria, euphoria, exacerbation of tics, Change in libido, growth suppression, Frequent erections, impotence, prolonged erection, Rhabdomyolysis, tremor.
Interaction :
Antipsychotic Agents: May diminish the stimulatory effect of Amphetamines.
CYP2D6 Inhibitors: May increase the serum concentration of Amphetamines.
Linezolid: May enhance the hypertensive effect of Sympathomimetics.
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines.
Opioid Analgesics: Amphetamines may enhance the analgesic effect of Opioid Analgesics.
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.
Hepatic Dose :
No dosage adjustments are recommended.